Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Mar 11;39(12):1383–1388. doi: 10.1200/JCO.20.03565

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 by American Society of Clinical Oncology

PMC Copyright notice

FIG 2. — ER modulators that are currently approved for use in the treatment or prevention of ER-positive breast cancers or that are currently in clinical development. Those drugs (SERDs and SERMs) that are currently approved for clinical use in breast cancer are highlighted in green. Investigational drugs that are currently in development for breast cancer are as follows: AZD9833 (NCT04588298; SERENA-3), RG6171 (giredestrant) (NCT04576455), SAR439859 (amcenestrant) (NCT03284957; AMEERA-1), ZN-c5 (NCT03560531), G1T48 (rintodestrant) (NCT03455270), LY3844356 (NCT04188548; EMBER), D-0502 (NCT03471663), SHR9549 (NCT03596658), OP-1250 (NCT04505826), LSZ102 (NCT02734615), ARV-471 (NCT04072952), bazedoxifene (NCT02448771), RAD1901 (elacestrant) (NCT03778931; EMERALD), lasofoxifene (NCT03781063; ELAINE-1), and H3B-6545 (NCT04288089). The relative SERD or SERM activity reflects the authors' summary of the available literature and may change as more data become available from comparative studies. ER, estrogen receptor; SERD, selective estrogen receptor downregulator or degrader; SERM, selective estrogen receptor modulator.